EPO (erythropoietin; HGNC:3415, NCBI Gene ID 2056) is a human locus mapped to chromosome band 7q22.1 that encodes heavily glycosylated four-helix-bundle cytokine hormone Erythropoietin (165 mature aa; 30.4 kDa). EPO acts in renal PHD2-VHL-HIF2A (EPAS1) oxygen-sensing & bone marrow EPOR-JAK2-STAT5 erythropoiesis, together with Erythropoietin Hormone Physiology, Erythropoietin Glycoprotein Structure, and HIF1A (Hypoxia-Inducible Factor 1-Alpha Gene). Encodes erythropoietin, the hypoxia-inducible renal glycoprotein hormone governing red blood cell production in bone marrow.
Genomic Organization & Cytogenetic Locus: 5-exon gene on chromosome 7q22.1 flanked by kidney-inducible and liver-inducible hypoxia response elements (HREs, 5-prime-RCGTG-3-prime) bound by HIF-2alpha (EPAS1)/ARNT, encoding a 193-amino-acid precursor cleaved to a 166-residue peptide (165 aa in plasma after C-terminal Arg166 clipping) carrying three N-linked (Asn24, Asn38, Asn83) and one O-linked (Ser126) sialylated carbohydrate chains essential for in vivo circulatory survival.
Cellular & Tissue Expression Profile: In fetal life synthesized primarily by hepatic hepatocytes; after birth, production switches >90% to specialized peritubular interstitial fibroblast-like Type I cells (Norn cells) in the deep renal cortex and outer medulla of the kidneys.
Molecular Function & Pathways
Biochemical & Physiological Mechanism: When tissue oxygen tension falls (anemia, altitude, ischemia), prolyl hydroxylase domain enzyme 2 (PHD2 / EGLN1) ceases hydroxylating HIF-2alpha, allowing HIF-2alpha to escape VHL ubiquitylation and induce renal EPO transcription up to 1,000-fold; secreted EPO travels to bone marrow CFU-E and proerythroblast progenitors to homodimerize the erythropoietin receptor (EPOR) and activate JAK2-STAT5-BCL2L1 (Bcl-xL) anti-apoptotic survival and hemoglobin synthesis.
Clinical & Therapeutic Significance
Human Genetic Variants & Disease Phenotypes: Loss of renal EPO-producing interstitial cells in chronic kidney disease causes normocytic renal anemia, whereas rare germline gain-of-function mutations in the EPO promoter/intron or in the oxygen-sensing PHD2-VHL-HIF2A axis cause familial erythrocytosis (polycythemia).
Therapeutic & Clinical Pharmacology: Discovery of how cells sense oxygen to regulate EPO earned William Kaelin, Peter Ratcliffe, and Gregg Semenza the 2019 Nobel Prize in Physiology or Medicine; clinically harnessed via recombinant erythropoiesis-stimulating agents (epoetin alfa, hyperglycosylated darbepoetin alfa) and oral HIF-prolyl hydroxylase inhibitors (daprodustat, vadadustat, roxadustat) that reactivate endogenous EPO transcription.